Shan S Wong1, Fang-Chi Hsu2, Nancy E Avis3, Clancy J Clark4. 1. Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA. Electronic address: sswong@wakehealth.edu. 2. Department of Biostatistics and Data Science, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA. Electronic address: fhsu@wakehealth.edu. 3. Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA. Electronic address: navis@wakehealth.edu. 4. Division of Surgical Oncology, Department of General Surgery, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA. Electronic address: cjclark@wakehealth.edu.
Abstract
OBJECTIVES: This study compares health-related quality of life (HRQoL) of older patients with pancreatic ductal adenocarcinoma (PDAC) to controls without cancer, and examines the impact of medical comorbidities on HRQoL. MATERIALS AND METHODS: We conducted a case-control study using the 1998-2011 Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey (SEER-MHOS) linked dataset. Cases were Medicare beneficiaries aged 65 and older diagnosed with PDAC (N = 128) and matched controls were without a history of cancer (N = 512). We used the Short Form 36 (SF-36) and Veterans-RAND-12 (VR-12) to examine HRQoL and calculated mental (MCS) and physical (PCS) component scores. Linear regression and mixed effects models were used to examine the impact of medical comorbidities on MCS and PCS for cases and controls, respectively. RESULTS: Cases reported significantly poorer PCS (29.3 vs. 36.3) and MCS (44.8 vs. 49.9) compared to controls. Comorbidities were significantly associated with lower PCS and MCS in controls. However, neither total number of comorbidities or comorbidities grouped by organ systems (cardiopulmonary disease, musculoskeletal disease, diabetes) were significantly related to PCS or MCS for cases. Comparison of regression coefficients estimates did not indicate that lack of significance was due to differences in sample size. CONCLUSIONS: The results of this study highlight the poor HRQoL reported by older patients with PDAC. HRQoL scores were very low in this population, particularly in physical health status, which were not explained by comorbidities.
OBJECTIVES: This study compares health-related quality of life (HRQoL) of older patients with pancreatic ductal adenocarcinoma (PDAC) to controls without cancer, and examines the impact of medical comorbidities on HRQoL. MATERIALS AND METHODS: We conducted a case-control study using the 1998-2011 Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey (SEER-MHOS) linked dataset. Cases were Medicare beneficiaries aged 65 and older diagnosed with PDAC (N = 128) and matched controls were without a history of cancer (N = 512). We used the Short Form 36 (SF-36) and Veterans-RAND-12 (VR-12) to examine HRQoL and calculated mental (MCS) and physical (PCS) component scores. Linear regression and mixed effects models were used to examine the impact of medical comorbidities on MCS and PCS for cases and controls, respectively. RESULTS: Cases reported significantly poorer PCS (29.3 vs. 36.3) and MCS (44.8 vs. 49.9) compared to controls. Comorbidities were significantly associated with lower PCS and MCS in controls. However, neither total number of comorbidities or comorbidities grouped by organ systems (cardiopulmonary disease, musculoskeletal disease, diabetes) were significantly related to PCS or MCS for cases. Comparison of regression coefficients estimates did not indicate that lack of significance was due to differences in sample size. CONCLUSIONS: The results of this study highlight the poor HRQoL reported by older patients with PDAC. HRQoL scores were very low in this population, particularly in physical health status, which were not explained by comorbidities.
Authors: H D Heerkens; D S J Tseng; I M Lips; H C van Santvoort; M R Vriens; J Hagendoorn; G J Meijer; I H M Borel Rinkes; M van Vulpen; I Q Molenaar Journal: Br J Surg Date: 2015-11-19 Impact factor: 6.939
Authors: Asta Bye; Marit S Jordhøy; Grete Skjegstad; Oddlaug Ledsaak; Per Ole Iversen; Marianne Jensen Hjermstad Journal: Support Care Cancer Date: 2012-06-10 Impact factor: 3.603
Authors: Yang Deng; Huakang Tu; Jeanne A Pierzynski; Ethan D Miller; Xiangjun Gu; Maosheng Huang; David W Chang; Yuanqing Ye; Michelle A T Hildebrandt; Alison P Klein; Ren Zhao; Scott M Lippman; Xifeng Wu Journal: Eur J Cancer Date: 2018-02-03 Impact factor: 9.162
Authors: D P Kelsen; R K Portenoy; H T Thaler; D Niedzwiecki; S D Passik; Y Tao; W Banks; M F Brennan; K M Foley Journal: J Clin Oncol Date: 1995-03 Impact factor: 44.544
Authors: Mei R Fu; Deborah Axelrod; Amber A Guth; Charles M Cleland; Caitlin E Ryan; Kristen R Weaver; Jeanna M Qiu; Robin Kleinman; Joan Scagliola; Joseph J Palamar; Gail D'Eramo Melkus Journal: J Pers Med Date: 2015-06-26
Authors: Eric Havens; S Lane Slabaugh; Charles G Helmick; Tristan Cordier; Matthew Zack; Vipin Gopal; Todd Prewitt Journal: Prev Chronic Dis Date: 2017-07-27 Impact factor: 2.830